Genmab — Marts 2015
-
det er jo klart Solsen. Mener mange af analytikerne inklusiv Deutsche Bank har kalkuleret med ca. 60-70% markedsandel til Dara og så 10% til både MOR, SAR og Elutzumumab
-
så der er jo lidt ekstra til deling nu
-
-
ja bongo man kunne jo spekulere lidt i det
-
Novo ser ud til at åbne over 380
-
det vil trække hele bioteksektoren i DK med op håber jeg
-
Den handles ikke her?
-
500
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind